Upregulation and activation of eNOS by resveratrol
Taubert, D.; Berkels, R.
Circulation 107(11): E78
2003
ISSN/ISBN: 0009-7322 PMID: 12654625 Document Number: 560262
Document emailed within 1 workday
Related Documents
Giardina, S.; Michelotti, A.; Zavattini, G.; Finzi, S.; Ghisalberti, C.; Marzatico, F. 2010: Efficacy study in vitro: assessment of the properties of resveratrol and resveratrol + N-acetyl-cysteine on proliferation and inhibition of collagen activity Minerva Ginecologica 62(3): 195-201Kim, M.H.; Yoo, D.S.; Lee, S.Y.; Byeon, S.E.; Lee, Y.G.; Min, T.; Rho, H.S.; Rhee, M.H.; Lee, J.; Cho, J.Y. 2011: The TRIF/TBK1/IRF-3 activation pathway is the primary inhibitory target of resveratrol, contributing to its broad-spectrum anti-inflammatory effects Die Pharmazie 66(4): 293-300
Bobadilla, R.A.; Anguiano Robledo, L.; Mera Jiménez, E.; López Sanchez, P. 2003: Time course of COX and eNOS renal expression during rat pregnancy Proceedings of the Western Pharmacology Society 46: 58-60
Li, X.-W.; Hao, W.; Liu, Y.; Yang, J.-R. 2014: Effect of sequoyitol on expression of NOX4 and eNOS in aortas of type 2 diabetic rats Yao Xue Xue Bao 49(3): 329-336
Gómez-Fernández, P.; Sánchez-Margalet, V.; Ruiz, A.; García-Molina, F.; Medina, J.; Almaraz, M. 2004: Vascular expression of endothelial nitric oxide synthase (eNOS) in essential hypertension Nefrologia: Publicacion Oficial de la Sociedad Espanola Nefrologia 24(5): 486-488
Wiest, R.; Shah, V.; Sessa, W.C.; Groszmann, R.J. 1999: NO overproduction by eNOS precedes hyperdynamic splanchnic circulation in portal hypertensive rats American Journal of Physiology 276(4): G1043-G1051
An, J-dan.; Li, X-yuan.; Yu, J-bo.; Zhao, Y.; Jin, Z-shun. 2012: Association between the eNOS gene polymorphisms and rheumatoid arthritis risk in a northern Chinese population Chinese Medical Journal 125(8): 1496-1499
Kalinowski, L.; Dobrucki, I.T.; Malinski, T. 2002: Cerivastatin potentiates nitric oxide release and enos expression through inhibition of isoprenoids synthesis Journal of Physiology and Pharmacology: An Official Journal of the Polish Physiological Society 53(4 Part 1): 585-595
Nishevitha, N.S.; Angeline, T.; Jeyaraj, N. 2009: Endothelial nitric oxide synthase (eNOS) Glu298-->Asp polymorphism (G894T) among south Indians Indian Journal of Medical Research 129(1): 68-71
Celik, U.; Yildizdaş, D.çe.; Alhan, E.; Celik, T.; Attila, G.ül.; Sertdemir, Y.şa.; Tepe, T. 2008: Genetic dilemma: eNOS gene intron 4a/b VNTR polymorphism in sepsis and its clinical features in Turkish children Turkish Journal of Pediatrics 50(2): 114-119
Orgován, G.áb.; Noszál, B.él. 2015: Resveratrol in Pharmaceutical Chemistry Acta Pharmaceutica Hungarica 85(4): 123-129
Nau, J.-Y. 2010: Research on the virtues of resveratrol Revue Medicale Suisse 6(263): 1790-1791
Altorjay, I.; Veréb, Z.; Serfozo, Z.; Bacskai, I.; Bátori, R.; Erdodi, F.; Udvardy, M.; Sipka, S.; Lányi, Á.; Rajnavölgyi, É.; Palatka, K. 2011: Anti-TNF-alpha antibody (infliximab) therapy supports the recovery of eNOS and VEGFR2 protein expression in endothelial cells International Journal of Immunopathology and Pharmacology 24(2): 323-335
Furukawa, J.; Miyake, H.; Fujisawa, M. 2011: Upregulation of anti-apoptotic gene Nihon Rinsho. Japanese Journal of Clinical Medicine 69(Suppl 5): 117-120
Bradamante, S.; Piccinini, F.; Barenghi, L.; Bertelli, A.A.; De Jonge, R.; Beemster, P.; De Jong, J.W. 2000: Does resveratrol induce pharmacological preconditioning? International Journal of Tissue Reactions 22(1): 1-4
Braeuning, A. 2014: Does resveratrol inhibit NF-kappaB activity? Die Pharmazie 69(1): 54
Goldberg, D.M. 1996: More on antioxidant activity of resveratrol in red wine Clinical Chemistry 42(1): 113-114
Lin, J.K.; Tsai, S.H. 1999: Chemoprevention of cancer and cardiovascular disease by resveratrol Proceedings of the National Science Council Republic of China. Part B Life Sciences 23(3): 99-106
Rostad, K.; Mannelqvist, M.; Halvorsen, O.J.; Oyan, A.M.; Bø, T.H.; Stordrange, L.; Olsen, S.; Haukaas, S.A.; Lin, B.; Hood, L.; Jonassen, I.; Akslen, L.A.; Kalland, K.-H. 2007: ERG upregulation and related ETS transcription factors in prostate cancer International Journal of Oncology 30(1): 19-32
Bobrowska-Hägerstrand, M.; Lillås, M.; Mrówczyñska, L.; Wróbel, A.; Shirataki, Y.; Motohashi, N.; Hägerstrand, H. 2006: Resveratrol oligomers are potent MRP1 transport inhibitors Anticancer Research 26(3a): 2081-2084